What is the most recent earnings date for DCPH stock?
DECIPHERA PHARMACEUTICALS IN (DCPH) last reported earnings on 5/10/2024.
DECIPHERA PHARMACEUTICALS IN (DCPH) Earnings History & Surprises
NASDAQ:DCPH • US24344T1016
Current stock price
25.59 USD
+0.02 (+0.08%)
At close:
25.61 USD
+0.02 (+0.08%)
After Hours:
DCPH Earnings overview
Past quarterly earnings results for DECIPHERA PHARMACEUTICALS IN (DCPH), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Aug 7, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$0.52
- Revenue Estimate
- 50.622M
Last Reported
Most Recent- Release Date
- May 10, 2024
- Period
- Q1 / 2024
- EPS Reported
- -$0.52
- EPS Surprise
- 8.03%
- Revenue Surprise
- -9.86%
Beat Rate
Last 8 Quarters 75%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q1 2024 | -0.52 | -0.57 | 8.03% | 13.33% | 42.55M | 47.202M | -9.86% | 27.22% |
| Q4 2023 | -0.54 | -0.59 | 8.79% | 10.00% | 48.295M | 46.837M | 3.11% | 32.88% |
| Q3 2023 | -0.58 | -0.62 | 6.60% | -5.45% | 43.313M | 40.189M | 7.77% | 20.40% |
| Q2 2023 | -0.57 | -0.63 | 9.87% | 5.00% | 38.304M | 36.602M | 4.65% | 17.88% |
| Q1 2023 | -0.60 | -0.61 | 0.83% | 25.00% | 33.445M | 36.512M | -8.40% | 14.45% |
| Q4 2022 | -0.60 | -0.57 | -5.50% | 60.26% | 36.345M | 36.463M | -0.32% | 50.19% |
| Q3 2022 | -0.55 | -0.59 | 6.44% | 59.85% | 35.974M | 33.817M | 6.38% | 54.93% |
| Q2 2022 | -0.60 | -0.67 | 10.60% | 50.41% | 32.494M | 31.115M | 4.43% | 37.84% |
| Q1 2022 | -0.80 | -0.92 | 12.94% | 24.53% | 29.223M | 26.961M | 8.39% | 16.17% |
| Q4 2021 | -1.51 | -1.41 | -7.35% | -37.27% | 24.199M | 23.752M | 1.88% | 24.19% |
| Q3 2021 | -1.37 | -1.30 | -5.26% | -21.24% | 23.22M | 23.825M | -2.54% | 50.30% |
| Q2 2021 | -1.21 | -1.18 | -2.71% | -0.83% | 23.573M | 22.32M | 5.61% | 232.48% |
| Q1 2021 | -1.06 | -1.08 | 2.28% | 22.06% | 25.156M | 23.04M | 9.18% | 40,474.19% |
| Q4 2020 | -1.10 | -1.17 | 6.37% | - | 19.486M | 19.305M | 0.94% | - |
| Q3 2020 | -1.13 | -1.33 | 14.72% | - | 15.449M | 7.191M | 114.84% | - |
| Q2 2020 | -1.20 | -1.39 | 13.94% | - | 7.09M | 907.8K | 681.01% | - |
| Q1 2020 | -1.36 | -1.28 | -6.24% | - | 62K | 212.497K | -70.82% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
4
Average EPS beat (4)
8.32%
Max EPS beat (4)
9.87%
Min EPS beat (4)
6.60%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
1.42%
Max Revenue beat (4)
7.77%
Min Revenue beat (4)
-9.86%
Analysis
In the last 4 quarters, DCPH has consistently beaten EPS estimates in all releases
DCPH has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, DCPH has beaten the EPS estimates by 8.3% on average.
In the last 4 quarters, DCPH has beaten the revenue estimates by 1.4% on average.
Related analysis
DECIPHERA PHARMACEUTICALS IN / DCPH Earnings FAQ
Did DECIPHERA PHARMACEUTICALS IN (DCPH) beat earnings estimates last quarter?
DECIPHERA PHARMACEUTICALS IN (DCPH) beat EPS estimates and missed revenue estimates in the most recent quarter.
Can you provide information on how often DECIPHERA PHARMACEUTICALS IN beats earnings estimates?
In the last 4 quarters, DECIPHERA PHARMACEUTICALS IN (DCPH) has beaten EPS estimates in 4 out of 4 releases.